SEC Form 4 · accession 0001203311-17-000002
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Jan 6, 2017
Accepted (ET)
Jan 10, 2017 · 6:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 6, 2017 | M | 190 | $10.29 | A | 639,025 | D | |
| Common StockF1 | Jan 6, 2017 | S | 190 | $59.68 | D | 638,835 | D | |
| Common StockF1 | Jan 6, 2017 | M | 2,180 | $10.29 | A | 641,015 | D | |
| Common StockF3,F1 | Jan 6, 2017 | S | 2,180 | $58.86 | D | 638,835 | D | |
| Common StockF1 | Jan 6, 2017 | M | 8,053 | $10.29 | A | 646,888 | D | |
| Common StockF4,F1 | Jan 6, 2017 | S | 8,053 | $57.89 | D | 638,835 | D | |
| Common StockF1 | Jan 6, 2017 | M | 3,842 | $10.20 | A | 642,677 | D | |
| Common StockF5,F1 | Jan 6, 2017 | S | 3,842 | $57.40 | D | 638,835 | D | |
| Common StockF1 | Jan 6, 2017 | M | 200 | $10.20 | A | 639,035 | D | |
| Common StockF1 | Jan 6, 2017 | S | 200 | $55.26 | D | 638,835 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F6 | $10.20 | Jan 6, 2017 | M | 3,842 | D | — | May 25, 2017 | Common Stock | 3,842 | 16,365 | D |
| Non-Qualified Stock Option (right to buy)F6 | $10.20 | Jan 6, 2017 | M | 200 | D | — | May 25, 2017 | Common Stock | 200 | 16,165 | D |
| Non-Qualified Stock Option (right to buy)F7 | $10.29 | Jan 6, 2017 | M | 190 | D | — | Aug 28, 2017 | Common Stock | 190 | 83,184 | D |
| Non-Qualified Stock Option (right to buy)F7 | $10.29 | Jan 6, 2017 | M | 2,180 | D | — | Aug 28, 2017 | Common Stock | 2,180 | 81,004 | D |
| Non-Qualified Stock Option (right to buy)F7 | $10.29 | Jan 6, 2017 | M | 8,053 | D | — | Aug 28, 2017 | Common Stock | 8,053 | 72,951 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $58.55 to $59.53. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $57.52 to $58.51. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $56.66 to $57.52. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.
- F7Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares were fully vested on 8/28/11.